On April 25, 2022, Richard J. Wanstall, Chief Financial Officer, principal financial officer and principal accounting officer of Aileron Therapeutics, Inc., notified the Company of his resignation, effective May 6, 2022, to pursue another career opportunity. Mr. Wanstall's resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.